Company Mereo BioPharma Group PLC London S.E.
Equities
GB00BZ4G2K23
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Rare Disease Therapies
100.0
%
| 0 | nan % | 12 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
John P. Richard
FOU | Founder | 66 | 28/02/15 |
Founder | 64 | 09/07/15 | |
Charles Sermon
FOU | Founder | 55 | 28/02/15 |
Christine Fox
DFI | Director of Finance/CFO | 43 | 30/01/21 |
Michael Wyzga
CHM | Chairman | 69 | 22/04/19 |
Suba Krishnan
CTO | Chief Tech/Sci/R&D Officer | 59 | 06/12/20 |
John Lewicki
CTO | Chief Tech/Sci/R&D Officer | 72 | 30/06/20 |
Richard Francis
PRN | Corporate Officer/Principal | - | 31/07/19 |
Corporate Officer/Principal | 53 | 28/02/18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 22/04/19 |
Marc Yoskowitz
BRD | Director/Board Member | 49 | 09/11/22 |
Director/Board Member | 59 | 22/04/19 | |
Founder | 64 | 09/07/15 | |
Director/Board Member | 70 | 30/06/15 | |
Pierre Jacquet
BRD | Director/Board Member | 57 | 19/09/21 |
Justin Roberts
BRD | Director/Board Member | 42 | 09/11/22 |
Annalisa Jenkins
BRD | Director/Board Member | 58 | 09/11/22 |
Jeremy Bender
BRD | Director/Board Member | 52 | 30/09/20 |
Daniel Shames
BRD | Director/Board Member | 78 | 09/11/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 701,217,089 | 301,926,833 ( 43.06 %) | 0 | 43.06 % |
Company contact information
Mereo BioPharma Group Plc
1 Cavendish Place 4th Floor
W1G 0QF, London
+44 33 3023 7300
http://www.mereobiopharma.com![address Mereo BioPharma Group PLC](https://cdn.zonebourse.com/static/address/28607946.png)
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+20.63% | 127B | |
+23.21% | 117B | |
+25.44% | 27.67B | |
-20.17% | 20.33B | |
-16.45% | 16.79B | |
-18.07% | 15.63B | |
+11.92% | 14.84B | |
-47.70% | 14.65B | |
+58.32% | 14.43B |